Cardiovascular risk

Artikelen filtered by tag "cardiovascular risk"

The following articles contain the tag cardiovascular risk:

Reduction of cardiovascular risk with fish oil (Vazkepa)

In 2021, EMA published a favourable advisory report on the benefit-risk balance of the drug icosapent ethyl (EPA), branded as Vazkepa®, after which it was authorised for use in Europe. A large randomised placebo-controlled registration study foun ...

In short Read article

Cardiovascular safety of canagliflozin

Adding canagliflozin to an existing therapy in patients with type 2 diabetes and high cardiovascular risk is just as safe as adding a placebo, but may possibly offer only marginally greater cardiovascular protection than placebo. • Saving one pa ...

Read article